BPC-157 vs PACAP-38
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
Neuroprotective polypeptide with potent anti-inflammatory and cytoprotective properties discovered in 1989
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
BPC-157
250–500 mcg
PACAP-38
10–10 pmol/kg/min
Frequency
BPC-157
Once daily
PACAP-38
Once daily
Administration
BPC-157
Subcutaneous injection
PACAP-38
Intravenous infusion
Cycle length
BPC-157
4-6 weeks
PACAP-38
Ongoing/indefinite
Onset speed
BPC-157
Moderate (1-2 weeks)
PACAP-38
Moderate (1-2 weeks)
Evidence level
BPC-157
Strong preclinical (extensive animal studies)
PACAP-38
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Primary Benefit
Secondary Benefit
Additional Benefit
Neuroprotection
Anti-Inflammatory
Migraine Research
Compound specifications
BPC-157
Molecular formula
C62H98N16O22
Molecular weight
1419.53 g/mol
Half-life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS number
137525-51-0
PACAP-38
Molecular formula
C203H331N63O53S
Molecular weight
~4534 Da
Half-life
Very short plasma half-life (minutes); rapid enzymatic degradation
Bioavailability
IV: systemic; Intranasal: direct CNS access bypassing BBB; poor oral bioavailability
CAS number
137061-48-4
Dosing compared
BPC-157
Subcutaneous
250 mcg
Once daily · 1-2 weeks
A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
250-500 mcg
Twice daily · 4-6 weeks
Commonly used range for tissue and tendon recovery in research practice [1][3].
500 mcg
Twice daily · 6-8 weeks
Upper end used in practice for more demanding acute injuries [1][3].
PACAP-38
Intravenous
10 pmol/kg/min
Continuous infusion · 20-minute single infusion
Standardized human experimental-medicine provocation dose; 10 pmol/kg/min over 20 min was selected as the optimal/maximum tolerated rate after dose-finding (5-20 pmol/kg/min) and is reproduced across headache-model trials [6][7][8]. Used as a research provocation agent, not an approved therapeutic.
Best suited for
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair [1][7]
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions [1][11] - derived from gastric juice, it has a natural affinity for digestive tissue [3][5]
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression [8]
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties [9][10]
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms [2]
PACAP-38
Neuroprotection research
PACAP-38 is particularly well-suited for individuals focused on neuroprotection research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Stroke and traumatic brain injury investigation
PACAP-38 is particularly well-suited for individuals focused on stroke and traumatic brain injury investigation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Migraine pathophysiology studies
PACAP-38 is particularly well-suited for individuals focused on migraine pathophysiology studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-inflammatory mechanism research
PACAP-38 is particularly well-suited for individuals focused on anti-inflammatory mechanism research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
PACAP-38
Common
- Flushing
- Tachycardia
- Gastrointestinal Effects
- Transient Warmth Sensation
Uncommon
- Headache and Migraine Triggering
- Hypotension
Serious
- Systemic Hypotension and Cardiovascular Effects
- Systemic Inflammatory Activation
Safety & evidence
BPC-157
Evidence level
Strong preclinical (extensive animal studies)
FDA status
Research compound
Safety overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. [5] No FDA approval exists. [4][6] Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. [4][5] Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. [2][4] The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. [6][7] Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- Pregnancy
- Breastfeeding
- Active cancer
- History of cancer
PACAP-38
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Research compound
Safety overview
PACAP-38 shows good tolerability in Phase II trials for migraine and pain conditions with minimal serious adverse events at IV doses of 2-6 mcg/kg. Primary side effects are transient flushing and headache (10-15% of subjects), likely related to vasodilation. Cardiovascular effects include mild heart rate increase and blood pressure changes, monitored in clinical settings. No carcinogenicity or teratogenicity in animal models; limited long-term safety data in humans.
Contraindications
- Active migraine or headache disorder (PACAP-38 is a potent migraine trigger)
- Uncontrolled hypotension or cardiovascular instability
- Not approved for clinical use outside research settings
- Insufficient data for pregnancy and lactation safety
Which is right for you?
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health
Choose PACAP-38 if...
- Neuroprotection research
- Stroke and traumatic brain injury investigation
- Migraine pathophysiology studies
- Anti-inflammatory mechanism research